Related Experiment Video
Updated: Jan 19, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
Clinical Outcomes of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Chronic Liver Disease: A
Paul Ndunda1, Sachin Srinivasan1, Mohinder Vindhyal1
1Department of Internal Medicine, University of Kansas School of Medicine-Wichita, Wichita, KS.
Insights
Transcatheter aortic valve replacement (TAVR) may offer better outcomes for patients with chronic liver disease compared to surgical aortic valve replacement (SAVR). TAVR was associated with lower in-hospital mortality, reduced blood transfusions, and shorter hospital stays.
Area of Science:
- Cardiology
- Hepatology
- Interventional Cardiology
Background:
- Chronic liver disease significantly elevates cardiac surgical risks, with mortality rates varying widely based on disease severity (Child-Pugh class).
- Limited data exists comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) outcomes specifically in patients with liver disease.
Purpose of the Study:
- To compare the in-hospital outcomes of TAVR versus SAVR in patients suffering from chronic liver disease.
- To evaluate differences in mortality, blood transfusion requirements, hospital length of stay, discharge disposition, acute kidney injury, and hospitalization costs between TAVR and SAVR.
Main Methods:
- A systematic literature search was conducted across major databases (PubMed, Cochrane Library, Web of Science, Google Scholar).
- Five observational studies involving 359 TAVR patients and 1,872 SAVR patients were included.
- Risk of bias was assessed using the Risk of Bias in Non-Randomized Studies - of Interventions (ROBINS-I) tool.
Main Results:
- In propensity score-matched analyses, TAVR showed lower in-hospital mortality (7.3% vs 13.2%), reduced blood transfusion rates (27.4% vs 51.1%), and shorter hospital stays (10.9 vs 15.7 days) compared to SAVR.
- No significant differences were observed between TAVR and SAVR regarding discharge home rates, acute kidney injury incidence, or mean hospitalization costs.
- Overall analysis indicated a trend towards lower in-hospital mortality with TAVR, though not statistically significant (7.2% vs 18.1%).
Conclusions:
- Transcatheter aortic valve replacement (TAVR) appears to be a potentially safer alternative to surgical aortic valve replacement (SAVR) for patients with chronic liver disease.
- TAVR is associated with reduced in-hospital mortality, fewer blood transfusions, and shorter hospital stays in this high-risk patient population.
- Further research may be warranted to confirm these findings and optimize treatment strategies for liver disease patients undergoing aortic valve replacement.
Abstract:
Background: Chronic liver disease increases cardiac surgical risk, with 30-day mortality ranging from 9% to 52% in patients with Child-Pugh class A and C, respectively. Data comparing the outcomes of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with liver disease are limited. Methods: We searched PubMed, Cochrane Library, Web of Science, and Google Scholar for relevant studies and assessed risk of bias using the Risk of Bias in Non-Randomized Studies - of Interventions (ROBINS-I) Cochrane Collaboration tool. Results: Five observational studies with 359 TAVR and 1,872 SAVR patients were included in the analysis. Overall, patients undergoing TAVR had a statistically insignificant lower rate of in-hospital mortality (7.2% vs 18.1%; odds ratio [OR] 0.67; 95% confidence interval [CI] 0.25, 1.82; I2=61%) than patients receiving SAVR. In propensity score-matched cohorts, patients undergoing TAVR had lower rates of in-hospital mortality (7.3% vs 13.2%; OR 0.51; 95% CI 0.27, 0.98; I2=13%), blood transfusion (27.4% vs 51.1%; OR 0.36; 95% CI 0.21, 0.60; I2=31%), and hospital length of stay (10.9 vs 15.7 days; mean difference -6.32; 95% CI -10.28, -2.36; I2=83%) than patients having SAVR. No significant differences between the 2 interventions were detected in the proportion of patients discharged home (65.3% vs 53.9%; OR 1.3; 95% CI 0.56, 3.05; I2=67%), acute kidney injury (10.4% vs 17.1%; OR 0.55; 95% CI 0.29, 1.07; I2= 0%), or mean cost of hospitalization ($250,386 vs $257,464; standardized mean difference -0.07; 95% CI -0.29, 0.14; I2=0%). Conclusion: In patients with chronic liver disease, TAVR may be associated with lower rates of in-hospital mortality, blood transfusion, and hospital length of stay compared with SAVR.
More Related Videos
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
09:57Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
Related Concept Videos
12:17Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
09:57Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
14:14Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
07:46Automatic Surgery in Transcatheter Aortic Valve Replacement Using Augmented Reality
08:50Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement